유방 병변 국소화 방법 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 영상 유도 모달리티별, 병변 유형별, 시술 환경별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Breast Lesion Localization Methods Market Summary

The global breast lesion localization methods market size was valued at USD 1.2 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 2.2 billion by 2033, at a CAGR of 7.3% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 39.4% in 2025. The growth of the global breast lesion localization methods market is driven by the increasing incidence of breast cancer, rising adoption of breast-conserving surgery, technological advancements in localization techniques, and expanding access to early breast cancer diagnosis worldwide.

In addition, the market is driven by a growing shift toward wire-free breast lesion localization technologies, as healthcare providers seek solutions that improve surgical precision, patient comfort, and clinical efficiency. Unlike conventional wire-guided localization, wire-free systems allow localization markers to be placed before the day of surgery, reducing scheduling constraints and enhancing coordination between radiology and surgical teams. These technologies also eliminate external wires, improving patient experience while supporting accurate localization of non-palpable breast lesions. Continuous adoption by hospitals and breast care centers reflects increasing confidence in these advanced systems.

For instance, in July 2026, PIH Health Whittier Hospital became the first hospital in Los Angeles County and Orange County to transition to SCOUT MD wire-free localization technology. The advanced radar-based platform was introduced to improve surgical planning, increase localization precision, streamline clinical workflows, and enhance patient care by eliminating the need for traditional wire-guided localization procedures. This growing transition toward wire-free technologies is expected to support sustained market growth over the forecast period.

"PIH Health is committed to bringing the latest proven technologies to our patients and physicians," said James R. West, president and chief executive officer of PIH Health. "Becoming the first hospital in Los Angeles County and Orange County to transition to SCOUT MD reflects our continued investment in advanced, patient-centered care and our dedication to improving outcomes through innovation."

"SCOUT MD is a huge step in the surgical treatment of patients who are interested in breast conserving surgery," said Rashi Singh MD, breast surgeon at PIH Health Whittier Hospital. "This technology helps surgeons more accurately localize multiple lesions even within the same breast, while supporting a smoother experience for patients throughout their surgical process."

The infographic underscores the significant global burden of breast cancer, with approximately 2.43 million new cases, 693,660 deaths, and 8.15 million five-year prevalent cases reported in 2024. This growing patient population is directly increasing the demand for accurate breast lesion localization methods, particularly for non-palpable lesions detected through mammography, ultrasound, and MRI screening. As breast cancer screening programs expand and early-stage diagnoses become more common, healthcare providers are adopting advanced localization technologies such as magnetic seed, radar-based, RFID, and radioisotope-free systems to improve surgical precision and patient outcomes. Regions with the highest incidence and prevalence, including Asia, Europe, and North America, are expected to remain key markets for breast lesion localization methods due to rising breast-conserving surgeries, expanding screening infrastructure, and the increasing preference for minimally invasive, wire-free localization techniques.

Global Breast Lesion Localization Methods Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global breast lesion localization methods market report based on type, imaging guidance modality, lesion type, procedure setting, end use, and region:

• Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Wire-Guided Localization (WGL)
• Radioisotope-Based Localization
  • Radio-Guided Occult Lesion Localization (ROLL)
  • Radioactive Seed Localization (RSL)
• Magnetic Localization
  • Magnetic Seed Localization
  • Magnetic Tracer Localization
• Radar-Based Localization
• Radiofrequency Identification (RFID)-Based Localization
• Electromagnetic Localization
• Others
• Imaging Guidance Modality Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Mammography-Guided Localization
• Ultrasound-Guided Localization
• MRI-Guided Localization
• Tomosynthesis-Guided Localization
• Others
• Lesion Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Malignant Breast Lesions
• Benign Breast Lesions
• High-Risk Breast Lesions
• Procedure Setting Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Same-Day Localization Procedures
• Preoperative Localization Procedures (1-30 days before surgery)
• End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Hospitals
• Ambulatory Surgery Centers (ASCs)
• Specialty Breast Centers
• Diagnostic Imaging Centers
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Type
  • 1.1.2. Imaging Guidance Modality
  • 1.1.3. Lesion Type
  • 1.1.4. Procedure Setting
  • 1.1.5. End Use
  • 1.1.6. Regional scope
  • 1.1.7. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Breast Lesion Localization Methods Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising global incidence of breast cancer
    • 3.2.1.2. Increasing adoption of breast-conserving surgery (BCS)
    • 3.2.1.3. Growing shift toward wire-free breast lesion localization technologies
    • 3.2.1.4. Continuous technological advancements in localization devices
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of wire-free localization systems and disposable markers
    • 3.2.2.2. Limited high-quality randomized clinical evidence for newer localization methods
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Replacement of conventional wire-guided localization with wire-free technologies
    • 3.2.3.2. Expansion of breast cancer screening programs in emerging economies
    • 3.2.3.3. Increasing use of localization following neoadjuvant therapy
    • 3.2.3.4. Integration of localization systems with advanced breast imaging and digital surgical workflows
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Lack of standardized guidelines on the preferred localization method
    • 3.2.4.2. Reimbursement variability and budget constraints across healthcare systems
• 3.3. Breast Lesion Localization Methods Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Breast Lesion Localization Methods Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Breast Lesion Localization Methods Market: Type Movement Analysis, 2025 & 2033 (USD Million/Billion)
• 4.3. Global Breast Lesion Localization Methods Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
• 4.4. Wire-Guided Localization (WGL)
  • 4.4.1. Wire-Guided Localization (WGL) market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.4.2. Radioisotope-Based Localization
    • 4.4.2.1. Radioisotope-based localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.4.2.2. Radio-Guided Occult Lesion Localization (ROLL)
      • 4.4.2.2.1. Radio-Guided Occult Lesion Localization (ROLL) market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.4.2.3. Radioactive Seed Localization (RSL)
      • 4.4.2.3.1. Radioactive Seed Localization (RSL) market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.4.3. Magnetic Localization
    • 4.4.3.1. Magnetic localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.4.3.2. Magnetic Seed Localization
      • 4.4.3.2.1. Magnetic seed localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
    • 4.4.3.3. Magnetic Tracer Localization
      • 4.4.3.3.1. Magnetic tracer localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 4.5. Radar-Based Localization
  • 4.5.1. Radar-based localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 4.6. Radiofrequency Identification (RFID)-Based Localization
  • 4.6.1. Radiofrequency Identification (RFID)-based localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 4.7. Electromagnetic Localization
  • 4.7.1. Electromagnetic localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 4.8. Others
  • 4.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. Breast Lesion Localization Methods Market: Imaging Guidance Modality Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Breast Lesion Localization Methods Market: Imaging Guidance Modality Movement Analysis, 2025 & 2033 (USD Million/Billion)
• 5.3. Global Breast Lesion Localization Methods Market Size & Trend Analysis, by Imaging Guidance Modality, 2021 to 2033 (USD Million/Billion)
• 5.4. Mammography-Guided Localization
  • 5.4.1. Mammography-guided localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 5.5. Ultrasound-Guided Localization
  • 5.5.1. Ultrasound-guided localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 5.6. MRI-Guided Localization
  • 5.6.1. MRI-guided localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 5.7. Tomosynthesis-Guided Localization
  • 5.7.1. Tomosynthesis-guided localization market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 5.8. Others
  • 5.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. Breast Lesion Localization Methods Market: Lesion Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Breast Lesion Localization Methods Market: Lesion Type Movement Analysis, 2025 & 2033 (USD Million/Billion)
• 6.3. Global Breast Lesion Localization Methods Market Size & Trend Analysis, by Lesion Type, 2021 to 2033 (USD Million/Billion)
• 6.4. Malignant Breast Lesions
  • 6.4.1. Malignant breast lesions market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 6.5. Benign Breast Lesions
  • 6.5.1. Benign breast lesions market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 6.6. High-Risk Breast Lesions
  • 6.6.1. High-risk breast lesions market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. Breast Lesion Localization Methods Market: Procedure Setting Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Breast Lesion Localization Methods Market: Procedure Setting Movement Analysis, 2025 & 2033 (USD Million/Billion)
• 7.3. Global Breast Lesion Localization Methods Market Size & Trend Analysis, by Procedure Setting, 2021 to 2033 (USD Million/Billion)
• 7.4. Same-Day Localization Procedures
  • 7.4.1. Same-day localization procedures market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 7.5. Preoperative Localization Procedures (1-30 days before surgery)
  • 7.5.1. Preoperative localization procedures (1-30 days before surgery) market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 8. Breast Lesion Localization Methods Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Breast Lesion Localization Methods Market: End Use Movement Analysis, 2025 & 2033 (USD Million/Billion)
• 8.3. Global Breast Lesion Localization Methods Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million/Billion)
• 8.4. Hospitals
  • 8.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 8.5. Ambulatory Surgery Centers (ASCs)
  • 8.5.1. Ambulatory Surgery Centers (ASCs) market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 8.6. Specialty Breast Centers
  • 8.6.1. Specialty breast centers market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 8.7. Diagnostic Imaging Centers
  • 8.7.1. Diagnostic imaging centers market revenue estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 9. Breast Lesion Localization Methods Market: Regional Estimates & Trend Analysis by Type, Imaging Guidance Modality, Lesion Type, Procedure Setting, and End Use

• 9.1. Regional Dashboard
• 9.2. Market Size and Trend Analysis, 2021 to 2033
• 9.3. North America
  • 9.3.1. North America breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Competitive scenario
    • 9.3.2.3. Regulatory framework
    • 9.3.2.4. Reimbursement scenario
    • 9.3.2.5. U.S. breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Competitive scenario
    • 9.3.3.3. Regulatory framework
    • 9.3.3.4. Reimbursement scenario
    • 9.3.3.5. Canada breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Competitive scenario
    • 9.3.4.3. Regulatory framework
    • 9.3.4.4. Reimbursement scenario
    • 9.3.4.5. Mexico breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.4. Europe
  • 9.4.1. Europe breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.2. UK
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. Reimbursement scenario
    • 9.4.2.5. UK breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.3. Germany
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. Reimbursement scenario
    • 9.4.3.5. Germany breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. Reimbursement scenario
    • 9.4.4.5. France breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Competitive scenario
    • 9.4.5.3. Regulatory framework
    • 9.4.5.4. Reimbursement scenario
    • 9.4.5.5. Italy breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Competitive scenario
    • 9.4.6.3. Regulatory framework
    • 9.4.6.4. Reimbursement scenario
    • 9.4.6.5. Spain breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Competitive scenario
    • 9.4.7.3. Regulatory framework
    • 9.4.7.4. Reimbursement scenario
    • 9.4.7.5. Sweden breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Competitive scenario
    • 9.4.8.3. Regulatory framework
    • 9.4.8.4. Reimbursement scenario
    • 9.4.8.5. Denmark breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.4.9. Norway
    • 9.4.9.1. Key country dynamics
    • 9.4.9.2. Competitive scenario
    • 9.4.9.3. Regulatory framework
    • 9.4.9.4. Reimbursement scenario
    • 9.4.9.5. Norway breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. Reimbursement scenario
    • 9.5.2.5. China breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.3. Japan
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. Reimbursement scenario
    • 9.5.3.5. Japan breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. Reimbursement scenario
    • 9.5.4.5. India breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. Reimbursement scenario
    • 9.5.5.5. South Korea breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Reimbursement scenario
    • 9.5.6.5. Australia breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Competitive scenario
    • 9.5.7.3. Regulatory framework
    • 9.5.7.4. Reimbursement scenario
    • 9.5.7.5. Thailand breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.6. Latin America
  • 9.6.1. Latin America breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Reimbursement scenario
    • 9.6.2.5. Brazil breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Competitive scenario
    • 9.6.3.3. Regulatory framework
    • 9.6.3.4. Reimbursement scenario
    • 9.6.3.5. Argentina breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
• 9.7. Middle East and Africa
  • 9.7.1. Middle East and Africa breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. Reimbursement scenario
    • 9.7.2.5. South Africa breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Reimbursement scenario
    • 9.7.3.5. Saudi Arabia breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Competitive scenario
    • 9.7.4.3. Regulatory framework
    • 9.7.4.4. Reimbursement scenario
    • 9.7.4.5. UAE breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Competitive scenario
    • 9.7.5.3. Regulatory framework
    • 9.7.5.4. Reimbursement scenario
    • 9.7.5.5. Kuwait breast lesion localization methods market estimates and forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Company Market Share Analysis, 2025
• 10.4. Company Heat Map Analysis
• 10.5. Strategy Mapping
  • 10.5.1. Expansion
  • 10.5.2. Mergers & Acquisition
  • 10.5.3. Partnerships & Collaborations
  • 10.5.4. New Technology Launches
  • 10.5.5. Research And Development
  • 10.5.6. Company Profiles
  • 10.5.7. Merit Medical Systems
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Hologic, Inc.
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. MOLLI Surgical (Stryker)
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. Sirius Medical Systems B.V.
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic initiatives
  • 10.5.11. Elucent Medical
    • 10.5.11.1. Company overview
    • 10.5.11.2. Financial performance
    • 10.5.11.3. Product Benchmarking
    • 10.5.11.4. Strategic initiatives
  • 10.5.12. Becton, Dickinson and Company (BD)
    • 10.5.12.1. Company overview
    • 10.5.12.2. Financial performance
    • 10.5.12.3. Product Benchmarking
    • 10.5.12.4. Strategic initiatives
  • 10.5.13. Cook Group Incorporated
    • 10.5.13.1. Company overview
    • 10.5.13.2. Financial performance
    • 10.5.13.3. Product Benchmarking
    • 10.5.13.4. Strategic initiatives
  • 10.5.14. Argon Medical Devices
    • 10.5.14.1. Company overview
    • 10.5.14.2. Financial performance
    • 10.5.14.3. Product Benchmarking
    • 10.5.14.4. Strategic initiatives
  • 10.5.15. IsoAid, LLC
    • 10.5.15.1. Company overview
    • 10.5.15.2. Financial performance
    • 10.5.15.3. Product Benchmarking
    • 10.5.15.4. Strategic initiatives
  • 10.5.16. Mammotome (Danaher Corporation)
    • 10.5.16.1. Company overview
    • 10.5.16.2. Financial performance
    • 10.5.16.3. Product Benchmarking
    • 10.5.16.4. Strategic initiatives
  • 10.5.17. Geotek Medical
    • 10.5.17.1. Company overview
    • 10.5.17.2. Financial performance
    • 10.5.17.3. Product Benchmarking
    • 10.5.17.4. Strategic initiatives